key: cord-0977737-rf8jz3fz
authors: Tao, Yanyi; Tang, Liang V.; Hu, Yu
title: Treatments in the COVID-19 pandemic: an update on clinical trials
date: 2020-06-17
journal: Expert opinion on emerging drugs
DOI: 10.1080/14728214.2020.1773431
sha: ece23ac8bb9cd88c0037df062532852708892bdc
doc_id: 977737
cord_uid: rf8jz3fz

nan

The coronavirus disease-19 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly and widely around the world, with more than 4,900,000 confirmed cases and more than 320,000 deaths reported as of 20 May 2020. The most common clinical symptoms are fever, cough, fatigue, and dyspnea, and a few patients have some other symptoms such as headache, hemoptysis, and diarrhea [1] [2] [3] [4] . Previous experience in the treatment of coronavirus, such as SARS-COV and MERS-COV, has provided clinicians with a reference point for dealing with the novel coronavirus. Although there is still no specific drug, the increasing number of COVID-19 related reports around the world provide relevant insights for clinical treatment. This paper will summarize and discuss the current therapeutic drugs treating COVID-19 based on these reports of clinical trials.

COVID-19 belongs to the same genus of CoV as SARS-COV and MERS-COV, both of which are beta-cov. Whole genome sequencing showed that COVID-19 shared 79.5% of sequence identity with SARS-CoV [5] . In combination with the treatment experience of SARS-COV and MERS-COV, several potential drugs have been proposed for treatment of SARS-CoV-2, including arbidol, chloroquine, and human immunodeficiency virus-1 (HIV-1) protease inhibitors (lopinavir/ritonavir), new nucleoside analogues (remdesivir, GS-5734) and convalescent plasma. As for clinical broad-spectrum antiviral drugs, neuraminidase inhibitors (oseltamivir, peramivir, zanamivir, etc.) are not recommended for clinical use, since the coronavirus does not produce neuraminidase. In addition, nucleoside analogues are not recommended neither due to their little efficacy in vitro experiments or existing clinical studies. However, nucleoside analogues can be used in combination with interferon for antiviral treatment [6, 7] .

Arbidol (umifenovir) is a broad-spectrum antiviral compound approved in several countries for prophylaxis and treatment of influenza. It has been shown to inhibit SARS-CoV-2 in vitro [8] .

In vivo, several retrospective studies have discussed the antiviral effects and safety of arbidol in patients with COVID-19. A study comprising 69 patientsfound that arbidol could improve the rate of discharge and without deaths occurred [9] . Another study showed that the participant group that was given arbidol had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group, and no side effects were observed [10] . In addition, when compared tolopinavir/ritonavir only, combination group of arbidol and lopinavir/ritonavir was treatment significantly elevated negative conversion rate of coronavirus' test in 7-day and 14-day, and improved the chest CT scans in 7-day [11] . However, a retrospective study found that for non-ICU COVID-19 patients, arbidol might not accelerate SARS-CoV-2 clearance nor improve prognosis, compared to the control group [12] . These reports are all retrospective studies with a small sample size, and the conclusions are controversial. The efficacy and safety of arbidol needs to be further verified through randomized controlled clinical trials. Additionally, the current clinical dosage of arbidol (200 mg, 3 times/day) may not be the ideal dosage to inhibit SARS-CoV-2 infection [8, 13] ; whether a higher dosage of arbidol is required for COVID-19 patients needs to be studied.

Chloroquine has been widely used for prophylactic and curative treatment of malaria, and its anti-coronavirus properties was firstly reported in 2006 [14] . Several studies confirmed the efficacy of hydroxychloroquine and chloroquine on COVID-19 in in-vitro and preliminary in-vivo clinical trials [15, 16] . Further, hydroxychloroquine was found to be more potent than chloroquine in inhibiting SARS-CoV-2 in-vitro [17] . Based on existing reports of clinical trials of hydroxychloroquine and chloroquine, a recent systematic review and meta-analysis found that compared to control/conventional treatment, hydroxychloroquine seems to be promising in terms of less number of cases with radiological progression, less time to body temperature normalization, and lower total cough days. However, no difference was observed in terms of virological cure (OR 2.37, 0.13-44.53), death or clinical worsening of disease (OR 1.37, 1.37-21.97), and safety (OR 2.19, 0.59-8.18) [18] . Some studies reported that chloroquine combined with azithromycin has a synergistic effect on the treatment of COVID-19 [19, 20] ; but the findings are limited by the fact that most of the data was from the same research group and the sample size was small. Another study did not find any strong antiviral activity or clinical benefit in hospitalized patients with severe COVID-19 when treated with a combination of hydroxychloroquine and azithromycin [21] . Thus, the benefit of combined chloroquine and Azithromycin treatment remain to be explored. Further, chloroquine has a wide range of adverse effects on cardiac function and conduction, including the risk of arrhythmia at high doses or even therapeutic doses, which may lead to prolonged QT interval or increased risk of Torsade DE Pointes (TdP) [22] . Cardio vascular complications are common in COVID-19 patients and are associated with poor prognosis [23, 24] ; the use of chloroquine may further negatively affect prognosis of such patients. Similarly, azithromycin might prolong the QT interval [25] . In clinical practice, doctors should pay enough attention to the patient's cardiac status before and during medication so as prevent time loss. To sum up, although hydroxychloroquine and chloroquine are cheap and promising drugs against SARS-CoV-2, they may also cause serious side effects and more clinical data is required to prove their efficacy and safety [26] .

Lopinavir/ritonavir (LPV/r) has been shown to inhibit virus replication in-vitro, in animal experiments, and to improve clinical outcomes in patients with SARS-COV or MERS-COV, making it a potential therapeutic option for SARS-CoV-2 [27] . Efficacy of lopinavir/ritonavir in the clinical treatment of COVID-19 has been discussed in many cases (Table 1) . A newly reported retrospective single-center study of 94 patients found that the treatment regimen of interferon alfa (INF-α) + lopinavir/ritonavir and INF-α+ lopinavir/ritonavir + ribavirin may be beneficial for the treatment of COVID-19. In patients receiving this treatment, the clearance time of COVID-19 mRNA was positively correlated with the length of stay at the hospital. The clearance rate of COVID-19 mRNA was found to be significantly correlated with the decrease of serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels. A decrease in serum LDH or CK may indicate a good response to COVID-19 therapy [28] . Another study comprising 10 patients also confirmed the positive effect of lopinavir on COVID-19, suggesting that eosinophil count was a predictor of disease progression [29] . Changes in these biochemical factors provide new indicators for clinical observation during treatment. Further, a study reported that the combination treatment of LPV-r and routine adjuvant medicine against pneumonia could produce much better efficacy on patients with COVID-19 infection compared to treatment with adjuvant medicine alone [30] . The limitation of the above mentioned three reports is that the number of cases is limited and more clinical data is needed for verification. However, several studies did not find any clinical benefits of lopinavir/ritonavir, suggesting that lopinavir/ritonavir had no significant effect on mortality and virus clearance in patients [4, 27, [31] [32] [33] [34] . A randomized, controlled, open-label trial involving 199 patients reported that treatment with lopinavir/ritonavir did not affect time to clinical improvement as compared to the standard-care group (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days and the percentage of patients with detectable viral RNA at various time points were similar in the lopinavir/ritonavir group and the standard-care group. Adverse gastrointestinal effects were more common in the lopinavir/ritonavir group, but the standard-care group experienced more serious gastrointestinal problems [34] . An observational cohort study from China found that arbidol and LPV/r did not promote the transformation of swab virus nucleic acid into negative nor did it improve symptoms in COVID-19 patients. Further, there was no significant increase in the incidence of adverse reactions after the combination of LPV-r or arbidol, such as gastrointestinal symptoms, which deter improvement of the disease [35] . The efficacy of lopinavir/ritonavir in the treatment of COVID-19 remains to be verified by further studies. Meanwhile, note that if there are adverse effects to lopinavir/ritonavir, such as diarrhea, nausea, stomatitis, fever, anemia, leukopenia, and hyperbilirubinemia, the use of the drug should be suspended or discontinued, as may be appropriate [36] .

Remdesivir appeared to be greatly effective in treating the cases of SARS-CoV and MERS-CoV. The inhibition of SARS-COV-2 by remdesivir has been verified in-vitro and in animal experiments, and it is superior to the effects of lopinavir/ritonavir combined with interferon-therapy [15, 41] . For patients withCOVID-19, a study reports that 36 of 53 patients (68%) with severe COVID-19 who received remdesivir saw clinical improvement [42] . Acase of COVID-19 infection successfully cured by remdesivir was also reported in the US, and the patient showed significant improvement in clinical symptoms within 24 hours after treatment [43] . However, a randomized, double-blind, placebo-controlled multicenter study containing 237 patients found that compared to placebo, intravenous remdesivir did not significantly improve time to clinical improvement, mortality, or time to clearance of virus in patients with serious COVID-19. However, in patients treated within 10 days of symptom onset, remdesivir was nota significant factor, but was associated with a five-day reduction in the median time for clinical improvement [44] . The benefits of remdesivir for the treatment of COVID-19 are still uncertain, and larger sample sizes are needed to deepen our understanding of the treatment of COVID-19 with remdesivir.

As a classic form of adaptive immunotherapy, convalescent plasma has been used for the prevention and treatment of many infectious diseases. Convalescent plasma is considered adirect and effective treatment option for COVID-19 due to the lack of a vaccine [45] . The plasma of patients recovering from COVID-19 may contain antibodies against the virus that causes the disease, which are effective against infection. The US Food and Drug Administration (FDA) has approved the use of convalescent plasma for the treatment of critically ill patients with COVID-19, and it also highlighted the need for clinical trials to prove the effectiveness and safety of convalescent plasma therapy [46] . Three reports documented 21 patients with COVID-19 after convalescent plasma therapy; all reported that convalescent plasma seemed to save lives, and no serious adverse reactions have been found in COVID-19 patients 12 (33%) of 36 patients had been discharged in the arbidoltreated group, whereas 6 (19%) of 31 patients had been discharged in the arbidol-untreated group. All deaths occurred in the arbidol-untreated group.

Retrospective cohort study From January 16 to 29 January 2020.

[9]

Oral arbidol and LPV-r in the combination group and oral LPV-r only in the monotherapy group for 5-21 days The SARS-CoV-2 could not be detected for 12(75%) of 16 patients' nasopharyngeal specimens in the combination group after seven days, compared with 6 (35%) of 17 in the monotherapy group (p < 0 · 05). After 14 days 15(94%) of 16 and 9 (52 · 9%) of 17, respectively, SARS-CoV-2 could not be detected (p < 0 · 05). The chest CT scans were improving for 11(69%) of 16 patients in the combination group after seven days, compared with 5(29%) of 17 in the monotherapy group (p < 0 · 05).

Retrospective cohort study From 17 January 2020, to 13 February 2020 [11] Lopinavir/ritonavir group(n = 34) received 400 mg/100 mg of lopinavir/ritonavir twice a day for a week, the arbidol group (n = 16) was given 0. A 10-day course of remdesivir (200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment) Clinical improvement was observed in 36 of 53 patients (68%) after treatment.

Observational study From January 25,2020 to 30 March 2020 [42] Patients received either intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions, n = 158) or the same volume of placebo infusions for a total of 10 days (n = 79)

Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1 · 23 [95% CI 0 · 87-1 · 75]). Patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio [33] using convalescent plasma [47] [48] [49] . All of them have the limitation of small sample size and no control, so larger sample size randomized controlled trials are needed to strictly prove their effectiveness. In addition to studies on the efficacy and safety of convalescent plasma, the optimal dose, and the optimal time point of treatment also need to be considered [48, 50] .

Tocilizumab is commonly used adjuvant therapies for COVID-19 ( Table 2 ). The use of tocilizumab is based on the observation of excess pro-inflammatory cytokine production mediated cytokine storms in critically ill patients infected with COVID-19 [3, 33] . Anti-interleukin-6 (IL-6) may play a key role in cytokine storms [51, 52] . In a retrospective multi-center study of 150 patients in Wuhan city, IL-6 levels in patients were found to be a clinical predictor of COVID-19 mortality [53] . IL-6 is a potential therapeutic target for COVID-19 patients to prevent or relieve cytokine storms. As the first IL-6 blocking antibody to be marketed by targeting IL-6 receptors, tocilizumab appears to be an effective therapeutic option. Tocilizumab has been approved in China to treat patients with severe complications from COVID-19 that show elevated IL-6 plasmalevels, but no reliable evidence has been published regarding the safety or efficacy of tocilizumab in the treatment of COVID-19 patients. Retrospective studies have found that most patients with severe COVID-19 have improved clinical symptoms and good prognosis after treatment with [56] Tocilizumab was administered at a dosage of 8 mg/kg by two consecutive intravenous infusions 12 h apart (a third infusion was optional based on clinical response)

Overall, at 10 days, the respiratory condition was improved or stabilized in 77 (77%) patients, of whom 61 showed a significant clearing of diffuse bilateral opacities on chest x-ray and 15 were discharged from the hospital. Respiratory condition worsened in 23 (23%) patients, of whom 20 (20%) died.

100 Prospective single-center study From March 9 to 20 March 2020 [57] tocilizumab [51, 54, 55] . Compared with standard treatment alone, administering tocilizumab can reduce the rate of hospitalization and/or mortality in the intensive care unit ofCOVID-19 patients [56] . However, the sample size of these studies is small, and there may be bias. A recent prospective study in a single center with 100 patients from Italy found that patients with severe COVID-19 pneumonia with hyper inflammatory syndrome and acute respiratory failure responded to tocilizumab rapidly and continually, and with significant clinical improvements [57] . However, it is important to note that tocilizumab may cause serious adverse reactions, such as intestinal perforation, candida infection, and lipid metabolism disorder [58] [59] [60] .

There is no specific drug to treat COVID-19 up to date. Due to the lack of clinical data, the discussion on the efficacy and safety of drugs for the treatment of COVID-19 remain controversial and limited. More centralized, randomized, controlled, double-blind clinical trials are needed to establish effectiveness and safety of drugs for treating COVID-19.

This paper was not funded.

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Controversial treatments: an updated understanding of the coronavirus disease 2019

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

Clinical features of 69 cases with coronavirus disease

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study

Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study

Quadruple therapy for asymptomatic COVID-19 infection patients

Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol

This study suggested that chloroquine might increase cardiac toxicity in patients with COVID −19

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality

Risk evaluation of azithromycin-induced QT prolongation in real-world practice

Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)

A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option

The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients

Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression

Clinical efficacy of lopinavir/ritonavir in the treatment of coronavirus disease 2019

Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19

phase 2 trial in the study showed that treatment with lopinavir/ritonavir did not affect time to clinical improvement, as compared to the standard care group

Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19: an observational cohort study

Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers

Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma

Compounds with therapeutic potential against novel respiratory 2019 coronavirus

Compassionate use of remdesivir for patients with severe Covid-19

First case of 2019 novel coronavirus in the United States

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Pivotal phase 2 trial in this study found that, compared with placebo, intravenous remdesivir did not significantly improve the time to clinical improvement, mortality, or time to clearance of virus in patients with serious COVID-19

Convalescent plasma in Covid-19: possible mechanisms of action

Covid-19: FDA approves use of convalescent plasma to treat critically ill patients

Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Treatment with convalescent plasma for COVID-19 patients in Wuhan

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Why tocilizumab could be an effective treatment for severe COVID-19?

Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients

This prospective study found that severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure responded to tocilizumab rapidly, continually, and with significant clinical improvements

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Tocilizumab treatment in COVID-19: a single center experience

Effective treatment of severe COVID-19 patients with tocilizumab

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia

Tocilizumab in COVID-19: beware of risk of intestinal perforation

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?

Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab